Live Breaking News & Updates on Neck Surg

Stay updated with breaking news from Neck surg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Business News | Rakuten Medical to Start a Global Phase 3 Trial of Alluminox Treatment Using ASP-1929 for Recurrent Head and Neck Cancer in India

Get latest articles and stories on Business at LatestLY. Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical trial (ASP-1929-301/ClinicalTrials.gov Identifier: NCT03769506) evaluating Alluminox treatment (photoimmunotherapy) using ASP-1929 in patients with locoregional, recurrent head and neck squamous cell carcinomas (HNSCC) in India, and the registration of clinical trial information with the Clinical Trial Registry of India (CTRI) has been completed (CTRI Identifier: CTRI/2023/05/052728). The study sites will include several leading medical institutions in India such as the Tata Memorial Centre and Narayana Health, and the treatment will be administered to enrolled patient ....

New Delhi , Mickey Mikitani , Rakuten Medical Inc , Public Health , Narayana Health , Ministry Of Health , Indian Central Drugs Standard Control Organization , Centers For Disease , Global Adult Tobacco Survey , Drug Administration , Ministry Of Health Family Welfare , International Agency For Research On Cancer , Tata Memorial Centre , Businesswire India , Rakuten Medical , Clinical Trial Registry , Fast Track , Laser System , Conditional Early Approval , Global Cancer Observatory , International Agency , Adult Tobacco Survey , India Fact Sheet , Disease Control , Smokeless Tobacco , Family Welfare ,

Rakuten Medical to Start a Global Phase 3 Trial of Alluminox™ Treatment Using ASP-1929 for Recurrent Head and Neck Cancer in India

Rakuten Medical, a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization CDSCO to conduct its global, pivotal Phase 3 clinical trial ASP-1929-301ClinicalTrials.gov Identifier NCT03769506 evaluating Alluminox treatment photoimmunotherapy using ASP-1929 in patients with locoregional, recurrent head and neck squamous cell carcinomas HNSCC in India, and the registration of clinical trial information with the Clinical Trial Registry of India CTRI has been completed CTRI Identifier CTRI202305052728. ....

New Delhi , United States , Hisataka Kobayashi , Mickey Mikitani , Centers For Disease , Drug Administration , Global Adult Tobacco Survey , Tata Memorial Centre , Ministry Of Health , Rakuten Medical Inc , Narayana Health , Japanese Ministry Of Health , Indian Central Drugs Standard Control Organization , International Agency For Research On Cancer , National Cancer Institute , Business Wire India Rakuten Medical Inc , Public Health , Ministry Of Health Family Welfare , Business Wire India Rakuten Medical , Rakuten Medical , Clinical Trial Registry , Fast Track , Laser System , Conditional Early Approval , Global Cancer Observatory , International Agency ,